Publications by authors named "Rachid Baz"

72Publications

Multiple myeloma presenting as an intramedullary spinal cord tumor: a case report and review of the literature.

J Med Case Rep 2020 Oct 16;14(1):189. Epub 2020 Oct 16.

Department of Neurosurgery, University of South Florida, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13256-020-02496-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566029PMC
October 2020

Patient-reported outcomes regarding radiation therapy in patients with multiple myeloma.

Acta Oncol 2020 Aug 4;59(8):983-987. Epub 2020 Jun 4.

Radiation Oncology Department, Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1772499DOI Listing
August 2020

A pharmacodynamic model of clinical synergy in multiple myeloma.

EBioMedicine 2020 Apr 5;54:102716. Epub 2020 Apr 5.

Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Dr, SRB 4th 24011, Tampa, FL 33612, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2020.102716DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136599PMC
April 2020

Selective inhibitors of nuclear export (SINEs) in myeloma: breakthrough or bust?

Expert Opin Drug Saf 2020 Feb 15;19(2):113-115. Epub 2020 Jan 15.

Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2020.1713088DOI Listing
February 2020

Multiple Myeloma Genomics - A Concise Review.

Acta Med Acad 2019 Apr;48(1):57-67

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5644/ama2006-124.242DOI Listing
April 2019

Quality of life in multiple myeloma: considerations and recommendations.

Expert Rev Hematol 2019 06 15;12(6):419-424. Epub 2019 May 15.

a Department of Malignant Hematology , H. Lee Moffitt Cancer Center and Research Institute , Tampa , FL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1613886DOI Listing
June 2019

Lenalidomide-based response-adapted therapy for older adults without high risk myeloma.

Br J Haematol 2019 03 12;184(5):735-743. Epub 2018 Dec 12.

Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15700
Publisher Site
http://dx.doi.org/10.1111/bjh.15700DOI Listing
March 2019

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

J Clin Oncol 2018 03 30;36(9):859-866. Epub 2018 Jan 30.

Dan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.5207DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905485PMC
March 2018

The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.

Ther Adv Hematol 2017 Jul 28;8(7):209-220. Epub 2017 Jun 28.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620717710171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495505PMC
July 2017

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

Blood 2017 06 8;129(25):3294-3303. Epub 2017 May 8.

Section of Bone Marrow Transplantation & Leukemia, Division of Oncology, Department of Medicine, Washington University, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-09-740787DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482100PMC
June 2017

Waldenström Macroglobulinemia: Review of Pathogenesis and Management.

Clin Lymphoma Myeloma Leuk 2017 05 7;17(5):252-262. Epub 2017 Mar 7.

Division of Hematology, Oncology, Blood, and Marrow Transplantation, Department of Medicine, University of Arizona, Tucson, AZ. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650163066
Publisher Site
http://dx.doi.org/10.1016/j.clml.2017.02.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413391PMC
May 2017

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.

J Hematol Oncol 2016 08 24;9(1):73. Epub 2016 Aug 24.

Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-016-0304-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997728PMC
August 2016

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.

Clin Cancer Res 2016 Mar 7;22(5):1067-75. Epub 2015 Oct 7.

Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia. Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, Virginia. Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia. Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775365PMC
March 2016

A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.

Cancer 2015 Oct 6;121(20):3622-30. Epub 2015 Jul 6.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29533DOI Listing
October 2015

Bortezomib plus dexamethasone results in a late organ response in primary heavy-chain amyloidosis without a hematologic response.

Hematol Oncol Stem Cell Ther 2015 Sep 23;8(3):138-9. Epub 2015 Feb 23.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Department of Oncologic Sciences, University of South Florida College of Medicine, Tampa, FL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hemonc.2015.01.002DOI Listing
September 2015

An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.

Eur J Haematol 2015 Nov 12;95(5):426-35. Epub 2015 Mar 12.

Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12509DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508238PMC
November 2015

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.

Semin Cancer Biol 2014 Aug 12;27:62-73. Epub 2014 Mar 12.

Department of Blood and Marrow Transplantation and Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2014.03.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108511PMC
August 2014

A preclinical assay for chemosensitivity in multiple myeloma.

Cancer Res 2014 Jan 5;74(1):56-67. Epub 2013 Dec 5.

Authors' Affiliations: Departments of Cancer Imaging and Metabolism, Molecular Oncology, Bone Marrow Transplantation, and Department of Hematologic Malignancies, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2397DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915502PMC
January 2014

Sequence of novel agents in multiple myeloma: an instrumental variable analysis.

Leuk Res 2013 Sep 25;37(9):1077-82. Epub 2013 Jun 25.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.06.005DOI Listing
September 2013

Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.

Biol Blood Marrow Transplant 2013 Aug 13;19(8):1144-51. Epub 2013 Feb 13.

Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.02.003DOI Listing
August 2013

Stemness of B-cell progenitors in multiple myeloma bone marrow.

Clin Cancer Res 2012 Nov 17;18(22):6155-68. Epub 2012 Sep 17.

Blood and Marrow Transplantation Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612-9497, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-0531DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500436PMC
November 2012

Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma.

Cell Oncol (Dordr) 2011 Dec 1;34(6):545-51. Epub 2011 Oct 1.

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13402-011-0060-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417352PMC
December 2011

Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.

Clin Lymphoma Myeloma Leuk 2011 Dec 2;11(6):507-11. Epub 2011 Aug 2.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2011.06.010DOI Listing
December 2011

Lenalidomide mode of action: linking bench and clinical findings.

Blood Rev 2010 Nov;24 Suppl 1:S13-9

The Institute of Cancer Research and Royal Marsden Hospital, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0268-960X(10)70004-7DOI Listing
November 2010

State-of-the-Art Management of Complications of Myeloma and Its Treatment.

Adv Hematol 2010 27;2010:343089. Epub 2010 Jun 27.

Blood and Marrow Transplant Department, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2010/343089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905716PMC
July 2011

Leptomeningeal myeloma as the sole manifestation of relapse: an unusual presentation.

Am J Med Sci 2010 Jan;339(1):81-2

Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MAJ.0b013e3181b61145DOI Listing
January 2010

Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.

Hum Pathol 2009 Mar 13;40(3):405-12. Epub 2008 Dec 13.

Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44120, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2008.09.006DOI Listing
March 2009

Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma.

Leuk Lymphoma 2007 Dec;48(12):2338-44

Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190701644330DOI Listing
December 2007

An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications.

BJU Int 2008 Mar 26;101(6):712-5. Epub 2007 Oct 26.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2007.07268.xDOI Listing
March 2008

G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.

J Clin Invest 2007 Oct;117(10):3107-17

Center for Hematology and Oncology Molecular Therapeutics, The Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI31122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1964509PMC
October 2007

Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia.

Leuk Res 2008 Mar 28;32(3):413-20. Epub 2007 Aug 28.

Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, 9500 Euclid Avenue R35, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2007.07.015DOI Listing
March 2008

Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia.

Cancer 2007 Oct;110(8):1752-9

Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.22976
Publisher Site
http://dx.doi.org/10.1002/cncr.22976DOI Listing
October 2007

Lenalidomide: the emerging role of a novel targeted agent in malignancies.

Drugs Today (Barc) 2007 Feb;43(2):85-95

Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2007.43.2.1037480DOI Listing
February 2007

The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma.

Haematologica 2006 Oct 7;91(10):1410-3. Epub 2006 Sep 7.

Myeloma Research Program, Cleveland Clinic, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
October 2006

Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review.

Cancer 2004 Aug;101(4):790-5

Internal Medicine Residency Program, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.20441DOI Listing
August 2004